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Glucocorticoids (GC) are commonly used anti-inflammatory drugs, but
long-term use can result in marked growth retardation in children due
to their actions on growth plate chondrocytes. To gain an insight into
the mechanisms involved in GC-induced growth retardation, we
performed Affymetrix microarray analysis of the murine chondro-
genic cell line ATDC5, incubated with 106 M dexamethasone (Dex)
for 24 h. Downregulated genes included secreted frizzled-related
protein and IGF-I, and upregulated genes included serum/GC-regu-
lated kinase, connective-tissue growth factor, and lipocalin 2. Lipoca-
lin 2 expression increased 40-fold after 24-h Dex treatment. Expres-
sion increased further after 48-h (75-fold) and 96-h (84-fold) Dex
treatment, and this response was Dex concentration dependent. Li-
pocalin 2 was immunolocalized to both proliferating and hypertrophic
growth plate zones, and its expression was increased by Dex in
primary chondrocytes at 6 h (3-fold, P  0.05). The lipocalin 2
response was blocked by the GC-receptor antagonist RU-486 and was
increased further by the protein synthesis blocker cycloheximide.
Proliferation in lipocalin 2-overexpressing cells was less than in
control cells (49%, P  0.05), and overexpression caused an increase
in collagen type X expression (4-fold, P  0.05). The effects of
lipocalin 2 overexpression on chondrocyte proliferation (64%, P 
0.05) and collagen type X expression (8-fold, P  0.05) were further
exacerbated with the addition of 106 M Dex. This synergistic effect
may be explained by a further increase in lipocalin 2 expression with
Dex treatment of transfected cells (45%, P  0.05). These results
suggest that lipocalin 2 may mediate Dex effects on chondrocytes and
provides a potential novel mechanism for GC-induced growth retar-
dation.
microarray; growth retardation
GLUCOCORTICOIDS (GC) ARE COMMONLY USED as anti-inflammatory
or immunosuppressive treatments, and it has been estimated
that 5–10% of children may require some form of GC therapy
during childhood (67). Since the introduction of GCs in the
treatment of rheumatoid arthritis over 50 years ago, the thera-
peutic applications of these drugs have greatly broadened to
encompass a large number of non-endocrine and endocrine
diseases (28). Despite intense efforts in optimizing therapy,
adverse effects of GC medication are still common, with
growth impairment being one of the commonest in childhood
(48, 49).
Normal cartilage formation and bone growth are dependent
on chondrocyte progression through the growth plate, as dem-
onstrated by a number of null mutations that have been intro-
duced in mice. The rate of longitudinal bone growth is con-
trolled through the precise regulation of chondrocyte prolifer-
ation, differentiation, hypertrophy, and apoptosis (18, 36). The
mechanisms by which GCs induce failure in the growth pro-
cess are presently unclear but are likely to include antagonism
of growth hormone (GH) secretion and action. It has been
shown that GCs inhibit pulsatile GH release (26, 27, 68),
reduce GH receptor expression, and inhibit IGF-I activity (64).
GCs also act locally to inhibit longitudinal bone growth, which
suggests a mechanism intrinsic to the growth plate. Baron and
colleagues (3) reported that local infusion of GC into the
growth plate decreased tibial growth with no effects on the
contralateral limb. In addition, both Silvestrini et al. (59) and
Smink et al. (60) reported that GC reduced growth cartilage
width by inhibiting chondrocyte proliferation and increasing
the apoptosis of terminal hypertrophic chondrocytes. Studies
by our group and others have also shown that GCs impair
chondrocyte proliferation and increase apoptosis (33, 35, 50,
53, 55, 61). However, the mechanisms by which GCs exert
control over chondrocyte dynamics are presently unclear. It is
likely that GCs affect a wide range of complex regulatory and
signaling networks involving cell matrix and intercellular in-
teractions to mediate chondrocyte proliferation and differenti-
ation.
In this study, Affymetrix microarray gene expression profil-
ing of ATDC5 cells was used to identify novel GC-responsive
chondrocyte genes in an attempt to further our understanding
of the processes involved in GC-induced growth retardation.
We then proceeded to characterize the regulation, expression,
and function of lipocalin 2, a secreted acute-phase protein that
is thought to have an anti-inflammatory function and is in-
volved in the transport of small hydrophobic molecules (21).
Lipocalin 2-deficient mice have compromised immunity when
subjected to bacterial infections but have no other obvious
phenotype (5, 22). In this study, we show that lipocalin 2 is
markedly increased in response to dexamethasone (Dex) in
chondrocytes and may play a role in exacerbating GC effects
on the growth plate.
MATERIALS AND METHODS
Cell culture. The ATDC5 chondrocyte cell line was obtained from
the RIKEN Cell Bank (Ibaraki, Japan), and cells were cultured at a
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density of 6,000 cells/cm2 in differentiation medium (DMEM-F12;
Invitrogen, Paisley, UK), 5% FCS (Invitrogen), 3  108 M sodium
selenite, 10 g/ml human transferrin (Sigma, Poole, UK), and 10
g/ml insulin (Sigma). Cells were differentiated at 37°C in a humid-
ified atmosphere containing 5% CO2 for 8–15 days, and Dex (final
concentration 106 M) was added to the cells at the indicated times.
We and others have previously shown that, from 8 days of differen-
tiation, ATDC5 cells express the chondrocyte marker gene collagen
type II, and by day 15 the cells display a terminally differentiating
phenotype with increased levels of collagen type X and aggrecan
expression and the formation of nodules (49, 16). To test lipocalin 2
expression following exposure to other antiproliferative treatments,
ATDC5 cells were cultured in the presence of ceramide (40  M),
TNF (10 ng/ml), or serum-free medium (SFM) for 48 h. The protein
synthesis blocker cycloheximide (CHX; 8 g/ml), and the GC recep-
tor antagonist RU-486 (105 M) were added to ATDC5 cells to
investigate the mechanisms involved in Dex-induced lipocalin 2
expression. Murine recombinant lipocalin 2 was added to the cells at
a range of concentrations (5–20 g/ml; R&D Systems, Abingdon,
UK) to analyze the effect of lipocalin 2 on cell proliferation. Control
cells received vehicle only.
cDNA microarray hybridization. Total RNA was extracted from
duplicate control and Dex-treated cultures at day 15 of differentiation
24 h following treatment using previously described methods (52).
Briefly, total RNA was extracted from chondrocytes by repeated
aspiration though a 25-gauge syringe needle in 1 ml of Ultraspec
(Biotecx, Houston, TX). After extraction with chloroform, RNA in the
aqueous phase was purified with isopropanol and bound to 50 l of
RNA Tack resin before washing with 75% ethanol. The RNA was
then eluted in 100 l of nuclease-free water and treated with DNase.
The quality of each sample was considered suitable by a 260/280 ratio
of greater than 1.9. Samples were sent to the UK Human Genome
Mapping Programme-Resource Centre (Cambridge, UK), where tar-
get preparation and hybridization to the Affymetrix Murine 430 2.0
GeneChip was carried out following the standard Affymetrix protocol
(http://www.affymetrix.com/support/technical/manuals.affx). This GeneChip
contains 39,000 full-length mouse genes and EST clusters from the
UniGene database. The data obtained from these hybridizations can be
viewed on the EMBL-EBI Array Express repository (http://www.
ebi.ac.uk/microarray-as/aer/?#ae-main[0]) (accession no. E-MEXP-
1244).
Microarray data analysis. The data obtained from the Affymetrix
hybridization was preprocessed using the RMA algorithm in Gene-
Spring 7.0 (Silicon Genetics). Each gene was then normalized to the
control sample. To assess differential gene expression between treat-
ments, expression values were further filtered by retaining only those
probe sets with a fold change of at least 1.5 in Dex samples compared
with Controls. A t-test was then carried out, and genes associated with
a P value  0.05 were regarded as statistically significant. This
analysis resulted in a gene list of 96 transcripts, whose expression was
significantly changed 1.5-fold or more in Dex-treated samples. Probe
set lists resulting from the comparison of Control vs. Dex samples
filtered using a 1.5-fold cut-off were assigned a molecular function
with the NetAffx annotation programme (http://www.affymetrix.com/
analysis). The choice of candidates from our short list that were
initially prioritized for future study was based on reviews of function,
likely relationship to GC action, and association with chondrocytes
and bone growth.
Quantitative PCR. Quantitative PCR (qPCR) was used to confirm
changes in the expression of selected genes. ATDC5 cells at day 15 of
culture were incubated with 106 M Dex for 24 h and RNA was
extracted. RNA samples or blanks (containing nuclease-free water in
place of RNA) were reverse transcribed in 20-l reactions with 200 ng of
random hexamers and 200 U of Superscript II reverse transcriptase using
the Superscript preamplification protocol (Invitrogen). qPCR was
performed using the Stratagene Mx3000P Real-Time QPCR System
(Stratagene, La Jolla, CA). Primers were designed using the software
program Primer3 (Whitehead Institute for Biomedical Research) and
were made to span at least one intron to identify any amplification
from contaminating genomic DNA by semiquantitative PCR. The
primers were as follows: lipocalin 2, forward 5°a¨-CAGAAG-
GCAGCTTTACGATG-3, reverse 5-CCTGGAGCTTGGAA-
CAAATG-3, product 134 bp; secreted frizzled-related protein-2,
forward 5-TACCACGGAAGCCTCTAAGC-3, reverse 5-CTCGCT-
TGCACAGAGATGTT-3, product 100 bp; connective tissue growth
factor (CTGF), forward 5-CCACCCGAGTTACCAATGAC-3, reverse
5-GACAGGCTTGGCGATTTTAG-3, product 146 bp; IGF-I, forward
5-GTGGACCGAGGGGCTTTTACTT-3, reverse 5-TTTGCAGCT-
TCGTTTTCTTGTTTG-3, product 246 bp (from 7) Lumican, forward
5-TGCTCGAGCTTGATCTCTCC-3, reverse 5-CAGTGGTCCCAG-
GATCTTACA-3, product 156 bp; integrin 10, forward 5-CTGAG-
GCTGGTTCACAATGA-3, reverse 5-CGGGAGGCTTCATTCAG-
TAG-3, product 138 bp; dentin matrix protein-1 (DMP1), forward
5-AAAGTCAAGCTAGCCCAGAGG-3, reverse 5-CCGGTCCCCG-
TACTCTTAG-3, product 129 bp; serum glucocorticoid-regulated ki-
nase (SGCK), forward 5-GATGGGCCTGAACGATTTTA-3, reverse
5-GAGGAGAGGGGTTAGCGTTC-3, product 111 bp. cDNA (10 ng)
derived from three control and three Dex-treated cultures were amplified
in triplicate using the Platinum SYBR Green qPCR SuperMix (Invitro-
gen) under the following conditions. cDNA was denatured for 2 min at
95°C, followed by 40 cycles consisting of 15 s at 95°C and 30 s at 60°C
and 1 cycle consisting of 1 min at 95°C and 30 s at 60°C. Each reaction
contained 10 l (10 ng) of cDNA, 25 l of Platinum SYBR Green qPCR
Super-Mix, 1 l of ROX Reference Dye, and 250 nM primer in a total
volume of 50 l. A dilution series of both gene of interest and external
control were carried out and subjected to an identical PCR to allow
estimation of PCR efficiency, and fold changes normalized for the
expression of GAPDH were calculated using the comparative method
(45). Initial experiments confirmed that lipocalin 2 expression was in-
creased by a similar level during both chondrogenesis (day 8) and
terminal differentiation (day 15) (data not shown). Consequently, for
characterization of lipocalin 2 expression in ATDC5 cells, Dex (106 to
109 M) was added to the cells on day 8 of culture for the stated time
periods.
Western blotting. Cells were lysed in RIPA buffer (20m M
Tris HCl, 135 mM NaCl, 10% glycerol, 1% Igepal, 0.1% SDS, 0.5%
deoxycholic acid, 2 mM EDTA) containing protease inhibitors (Com-
plete EDTA-free protease inhibitor cocktail; Roche, Mannheim, Ger-
many), and protein content was quantified using the DC-protein assay
reagent (Bio-Rad, Hercules, CA). Protein lysates (15 g) were loaded
onto 10% bis-tris gels, fractionated, and electroblotted onto nitrocel-
lulose membranes. After blocking with 5% nonfat milk powder and
0.1% Tween, the membranes were incubated overnight with anti-
lipocalin 2 primary antibody (1:500; R&D Systems) at 4°C, washed,
and incubated at room temperature for 1 h with rabbit anti-goat
peroxidase-labeled secondary antibody (1:2,000; DAKO, Cambridge,
UK). -Actin expression was also measured as a loading control
(anti--actin clone AC15, Sigma A5441, 1:5,000). The immune
complexes were then visualized by enhanced chemiluminescence (GE
Healthcare, Buckinghamshire, UK).
Analysis of ATDC5 proliferation with antiproliferative treatments.
Chondrocyte proliferation was assessed by incubating SFM, TNF
(10 ng/ml), or ceramide-treated (40 M) ATDC5 cells at day 8 of
maturation with 0.2 Ci/ml [3H]thymidine (37 MBq/ml; Amersham
Pharmacia Biotech, Buckinghamshire, UK) for the last 2 h of the
incubation period. Following removal of [3H]thymidine, the cells
were fixed in ice-cold TCA (5%) for 15 min, washed, and lysed in 0.1
M NaOH for up to 30 min. Scintillation fluid was then added, and the
amount of radioactivity incorporated into TCA-insoluble precipitates
was measured using a scintillation counter.
Histological analysis of lipocalin 2 expression in the growth plate.
Tibiae were dissected from 10-day-old and 5-wk-old C57BL6xCBA
mice that had been euthanized by cervical dislocation. Metatarsals
were dissected from 17-day-old fetal Swiss mice euthanized by
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Table 1. Upregulated GC-responsive chondrocyte genes as revealed by microarray analysis
Affymetrix ID Fold Induction by Dex Gene Name
Associated With Chondrocytes
or Bone Growth Associated With GCs
1427747_a_at 14.53 Lipocalin 2 *(63, 73) *(25)
1448550_at 7.98 Lipopolysaccharide binding protein *(46)
1428942_at 5.064 Metallothionein 2 *(56, 57)
1416125_at 3.877 FK506 binding protein 5
1442025_a_at 3.839 Similar to promyelotic leukemia zfp
1434202_a_at 3.607 Hypothetical protein MCG58343
1418187_at 3.583 Calcitonin receptor activity modifying protein *(23)
1448881_at 3.44 Haptoglobin acute phase response *(39)
1416953_at 3.324 Connective tissue growth factor *(38)
1425281_a_at 3.19 Delta sleep inducing peptide
1423233_at 3.131 CCAAT/enhancer binding protein delta *(40)
1449851_at 3.035 Chemokine ligand 2
1419874_x_at 2.983 Promyelotic leukaemia zinc finger protein
1420772_a_at 2.893 Delta sleep inducing peptide
1422557_s_at 2.847 Metallothionein 1 *(42)
1418091_at 2.731 Transcription factor CP2 like 1
1440235_at 2.69 Integrin alpha 10 *(4, 70)
1422878_at 2.591 Synaptotagmin 12
1416041_at 2.56 Serum/glucocorticoid regulated kinase *(40) *(65)
1428471_at 2.53 Sorbin and SH3 domain containing 1
1450826_a_at 2.508 Serum amyloid A 3
1455048_at 2.475 Immunoglobulin superfamily member 2
1423274_at 2.365 DEAD-H
1443745_s_at 2.332 Dentin matrix protein 1 *(19, 20, 72)
1426236_a_at 2.32 Glutamate ammonia ligase
1422573_at 2.108 AMP deaminase 3
1449254_at 2.02 Sectreted phosphoprotein 1
1418269_at 2.005 Lysyl oxidase-like 3
1448830_at 2.003 Dual specificity phosphatase 1
1417507_at 1.999 Cytochrome b-561
1434203_at 1.973 Hypothetical protein MCG58343
1438953_at 1.935 c-fos induced growth factor
1435943_at 1.905 Dipeptidase 1
1434642_at 1.9 Dehydrogenase/reductase member 8
1448842_at 1.894 Cysteine dioxygenase 1
1439755_at 1.837 Signal-induced proliferation-associated 1 like 1
1416383_a_at 1.835 Pyruvate carboxylase
1451596_a_at 1.834 Sphingosine kinase 1
1424051_at 1.823 Procollagen type IV *(34, 66)
1436789_at 1.818 Similar to FLJ14166 protein
1460011_at 1.793 Cytochrome p450
1452141_a_at 1.788 Selenoprotein P
1433832_at 1.782 Expressed sequence AI551766
1418932_at 1.768 Interleukin 3
1426195_a_at 1.756 Cystatin C
1422620_s_at 1.736 Phosphatidic acid phosphatase 2a *(37)
1422478_a_at 1.668 Acetyl coenzyme A synthetase 2
1417936_at 1.666 Chemokine ligand 9
1454675_at 1.665 Nuclear receptor subfamily 1 group D
1449731_s_at 1.657 Nuclear factor of kappa light chain gene enhancer
1448489_at 1.651 Platelet activating factor 2
1447602_x_at 1.646 Sulfatase 2 metbolism
1424671_at 1.645 Pleckstrin homology domain containing F
1437820_at 1.642 Forkhead-like 18
1451939_a_at 1.635 Sushi-repeat containing protein
1435254_at 1.627 Plexin B1
1456312_x_at 1.62 Gelsolin
1454849_x_at 1.619 Clusterin
1441926_x_at 1.616 Transmembrane inner ear
1430388_a_at 1.615 Sulfatase 2 metbolism
1459978_x_at 1.6 Similar to FLJ14166 protein
1448321_at 1.6 SPARC related modular calcium binding 1
1455078_at 1.593 Protein pdb:1LBG
1416825_at 1.579 Synotrophin acidic 1
1450678_at 1.565 Integrin beta 2 *(13)
1425894_at 1.565 cDNA sequence BC019711
1452296_at 1.554 Slit homolog 3
1426947_x_at 1.553 Procollagen type IV alpha 2
Continued
E1025Dex-INDUCED LIPOCALIN 2 EXPRESSION IN THE GROWTH PLATE
AJP-Endocrinol Metab • VOL 294 • JUNE 2008 • www.ajpendo.org
cervical dislocation. All mice were maintained by the Roslin Institute
Small Animal Unit in accordance with Home Office guidelines for the
care and use of laboratory animals. The limbs were fixed overnight in
4% paraformaldehyde at 4°C, decalcified for 5 days in 10% EDTA
(pH 8.0), dehydrated, and embedded in paraffin before sectioning at 6
m. For histological analysis, sections were dewaxed and demasked
for 30 min in 10 mM citrate buffer. Endogenous peroxidases and
nonspecific antibody binding were blocked with 3% H2O2 and normal
goat serum, respectively, before overnight incubation at 4°C with 2
g/ml anti-lipocalin 2 (R&D Systems). Following this, the sections
were washed in PBS and incubated with rabbit anti-goat IgG perox-
idase (1:100 dilution; DAKO) for 60 min. Diaminobenzidine (DAB)
substrate reagent (0.06% DAB, 0.1% H2O2 in PBS) was incubated for
8 min, rinsed in PBS, and counterstained with hematoxylin (Zymed,
Invitrogen) for 5 min. The sections were then dehydrated and mounted
in DPX.
Isolation of primary murine chondrocytes. Primary cultures of
chondrocytes from rib growth plates of newborn Swiss mice were
prepared using the isolation procedure and culture system developed
by Lefebvre et al. (41). Briefly, the rib cage and sternum were
dissected from 1-day-old mice, rinsed in PBS, and incubated at 37°C
for 30 min in 2 mg/ml pronase in PBS and then in 3 mg/ml
collagenase D in DMEM for 2 h. Soft tissues were detached from the
cartilage by repeated pipetting. The denser cartilage was allowed to
sediment, and the soft tissues were aspirated; the cartilage was then
further digested with collagenase D for 3 h. Undigested bony parts
were discarded, and the remaining cell suspension was aspirated
repeatedly with a pasteur pipette, filtered through a 45-m cell sieve,
rinsed first in PBS and then in serum-free DMEM, and cells were
counted. Chondrocytes were seeded in six-well plates at a density of
100,000 cells per well in DMEM with antibiotics, ascorbic acid, and
10% FBS. The cells were then cultured for 24 h, at which point Dex
(final concentration 106 M) was added to the cells for 6, 24, or 72 h.
Generation of lipocalin 2-overexpressing ATDC5 cells. Lipocalin 2
was amplified from ATDC5 cDNA and inserted into the EcoRI site of
the pWGB10 overexpression vector (a kind gift from Dr. Wei Cui,
Imperial College, London, UK). One microgram of pWGB10-lipoca-
lin 2 was transfected into 80% confluent ATDC5 cells with FuGene6
according to the manufacturer’s instructions (Roche Diagnostics,
Basel, Switzerland). Control cell lines were generated using the same
procedure with empty pWGB10 vector. After 48 h, cells were selected
in medium containing 2 g/ml puromycin, and after 2 wk clones were
isolated and lipocalin 2 expression was evaluated by PCR and West-
ern blotting.
Effect of lipocalin 2 overexpression on chondrocyte proliferation
and differentiation. To understand more fully the functional effects of
lipocalin 2 overexpression on chondrocyte function, we assessed
chondrocyte proliferation ([3H]thymidine uptake) and chondrocyte
differentiation (collagen type X expression). Chondrocyte prolifera-
tion was assessed in transfected ATDC5 cells at day 8 of maturation,
as previously described (49; also detailed above). Collagen type X
expression was measured by qPCR as described above. These exper-
iments determined whether the response of ATDC5 cells to Dex
treatment (106 M for 48 h) was modified in the presence of lipocalin
2 overexpression.
Table 1.—Continued
Affymetrix ID Fold Induction by Dex Gene Name
Associated With Chondrocytes
or Bone Growth Associated With GCs
1417872_at 1.544 Sprouty homolog 1
1428164_at 1.531 Nudix type motif 9
1415874_at 1.525 Period homolog 1
1420834_at 1.522 Vesicle-associated membrane protein 2
1455768_at 1.516 Niemann pick type C2
1437865_at 1.507 Spermatogenesis associated 13
1455158_at 1.504 Integrin alpha 3 *(70)
1427038_at 1.501 Preproenkephalin 1
1421037_at 1.5 Neuronal PAS domain protein 2
1421921_at 1.498 Cysteine protease inhibitor
GC, glucocorticoid; Dex, dexamethasone. *Nos. in parentheses refer to References.
Table 2. Downregulated GC-responsive chondrocyte genes as revealed by microarray analysis
Affymetrix ID
Fold Repression
by Dex Gene Name
Associated With Chondrocytes
or Bone Growth Associated With GCs
1418174_at 2.681 D site albumin promoter binding protein
1423607_at 2.232 Lumican *(34)
1451191_at 1.984 Cellular retinoic acid binding protein II
1423294_at 1.923 CPG2_Human coatomer gamma 2 subunit
1449855_s_at 1.887 Ubiquitin thiolesterase
1449486_at 1.876 Carboxylesterase 1
1448201_at 1.718 Secreted frizzled-related sequence protein 2 *(61)
1450243_a_at 1.692 Down syndrome critical region gene 1
1428950_s_at 1.664 Nucleolar protein 8
1454888_at 1.639 Prefoldin 4
1425357_a_at 1.618 Cysteine knot superfamily1
1450756_s_at 1.61 Cullin 3
1425806_a_at 1.546 SRB7
1417394_at 1.531 Kruppel-like factor 4 (gut)
1431056_a_at 1.529 Lipoprotein lipase
1436993_x_at 1.524 Four and a half LIM domains1
1437401_at 1.506 IGF-1 *(33, 61) *(33)
*Nos. refer to References.
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Statistical analysis. Analysis of variance (ANOVA) was performed
to determine statistical significance. General linear model analysis
incorporating pairwise comparisons using Tukey’s test was used to
compare groups within the ANOVA models. All data are expressed as
means 	 SE. Statistical analysis was performed using Minitab 14.
Statistical significance was accepted at P  0.05.
RESULTS
Identification and validation of dex-responsive chondrocyte
genes. Total RNA isolated from chondrogenic ATDC5 cells
was hybridized to the Affymetrix Murine 430 2.0 Array.
Analysis in GeneSpring 6.1 software demonstrated that from
39,000 transcripts the expressions of 96 genes were signifi-
cantly changed 1.5-fold or more (Tables 1 and 2). Gene
ontology analysis revealed that a large proportion of the genes
were involved in cell death, proliferation, skeletal develop-
ment, cell signaling, or cell adhesion (data not shown). A short
list of eight genes was selected for further analysis due to their
reported association with GC action and chondrocyte-mediated
bone growth. Transcripts upregulated by Dex included lipoca-
lin 2 (14.5-fold), CTGF (3.3-fold), integrin 10 (2.7-fold),
SGCK (2.6-fold), and DMP1 (2.3-fold). Transcripts downregu-
lated by Dex included Lumican (2.3-fold), secreted frizzled-
related protein-2 (SFRP) (1.7-fold), and IGF-I (1.5-fold). To
validate microarray data using independent methods, the eight
Dex-responsive genes listed above were selected for analysis
of gene expression by qRT-PCR. The induction of lipocalin 2,
SGCK, CTGF, integrin 10, and DMP1 paralleled the expres-
sion patterns obtained by microarray analysis, although the
fold change was much greater for qRT-PCR analysis (42-, 4.5-,
5.8-, 3.2-, and 5.7-fold, respectively; Fig. 1). Similarly, a
Fig. 1. Quantitative (q)PCR confirming changes in glucocorticoid-responsive
chondrocyte genes in ATDC5 cells. Eight genes identified by Affymetrix
microarray analysis were examined for changes in expression following 24-h
dexamethasone (Dex) incubation (106 M) in ATDC5 cells at day 15 of
maturation. See text for definitions. Data are expressed as means 	 SE; n 

3. ***P  0.001, **P  0.01.
Fig. 2. Characterization of lipocalin 2 expression in chondrocytes. A: alteration in lipocalin 2 expression in chondrogenic ATDC5 cells treated with 106 M Dex
for 1–168 h as measured by qPCR. Control, filled bars; Dex, open bars. B: dose-responsive change in lipocalin 2 expression in chondrogenic ATDC5 cells (day
8) with Dex over 48 h as measured by qPCR. C: expression of lipocalin 2 in primary murine chondrocytes treated with 106 M Dex for 6, 24, or 72 h as measured
by qPCR. Control, filled bars; Dex, open bars. Data are expressed as means 	 SE; n 
 3. ***P  0.001 vs. corresponding control. D: lipocalin 2 and -actin
protein expression in ATDC5 cells as measured by Western blotting after exposure to 106 M Dex for 48 h.
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6.5-fold downregulation of IGF-I expression was detected by
qRT-PCR analysis, although the downregulation of Lumican
and SFRP seen in the microarray data was not confirmed. From
these data, the expressions of six genes were confirmed to be
altered by 24-h Dex treatment. We chose lipocalin 2 for further
study because it had previously been shown to be upregulated
by Dex in various cell types (25), indicating that this may be a
generic mechanism by which GCs exert their antiproliferative
effects. Furthermore, the role of lipocalin 2 in regulating
chondrocyte function and bone growth is presently unknown.
Lipocalin 2 expression was induced 42-fold by Dex in ATDC5
cells during both chondrogenesis and terminal differentiation
(data not shown). Moreover, basal lipocalin 2 expression was
similar during both phases of maturation in these cells. Con-
sequently, ATDC5 cells in the chondrogenesis phase were used
to study the effect of lipocalin 2 on GC-induced growth
retardation.
Characterization of Dex-induced lipocalin 2 expression in
chondrocytes. qRT-PCR analysis was used to examine the
temporal effect of 106 M Dex on lipocalin 2 expression. No
effect was seen at 1 h, whereas Dex significantly (P  0.001)
increased lipocalin 2 expression at all other time points studied
(6–168 h), with an apparent plateau at 48 h (75-fold) (Fig. 2A).
Consequently, 48-h Dex incubation was used for all future
ATDC5 experiments. Dex-induced lipocalin 2 expression in
ATDC5 cells was also found to be concentration dependent
(Fig. 2B). At 106 M Dex, lipocalin 2 expression was 71-fold
higher than control samples. This response was reduced to 44-
and 13-fold at 107 and 108 Dex, respectively (P  0.001),
whereas no response was observed with 109 M Dex. Western
blotting confirmed that 106 M Dex increased lipocalin 2
protein expression at 48 h in ATDC5 cells (Fig. 2D). Primary
chondrocytes also expressed lipocalin 2, and this expression
was increased with 106 M Dex treatment (3-fold at 6 h, P 
0.001). This increased expression was maintained for up to
72 h (Fig. 2C). Taken together, the results indicate that Dex
regulates chondrocyte lipocalin 2 expression at both the mRNA
and protein levels and that the regulation of gene expression is
both time and concentration dependent.
Lipocalin 2 expression in the presence of antiproliferative
treatments. To measure lipocalin 2 expression with antiprolif-
erative treatments other than Dex (49), ATDC5 cells were
cultured in the presence of ceramide (40 M), TNF (10
ng/ml), or in SFM for 48 h. Proliferation was significantly
reduced in cells cultured in SFM, TNF, and ceramide (88.8,
98.4, and 21.2%, respectively, P  0.01; Fig. 3A). However,
unlike Dex, lipocalin 2 protein expression was not induced in
the presence of SFM or ceramide. A small increase in lipocalin
2 expression was observed with TNF (Fig. 3B).
Immunolocalization of lipocalin 2 expression within the
murine growth plate. Immunohistochemistry revealed that, in
metatarsals from 17-day-old fetal mice, lipocalin 2 was poorly
expressed in the proliferating chondrocytes, although strong
positive staining was evident in the prehypertrophic and hy-
pertrophic zones (Fig. 4A). The pattern of lipocalin 2 distribu-
tion appeared to change in the postnatal growth plate. In the
10-day-old epiphysis, greater lipocalin 2 expression was local-
ized to the proliferating chondrocytes (Fig. 4B), and this was
more clearly seen in the 5-wk-old growth plate, where intense
lipocalin 2 staining was observed in both the proliferating and
hypertrophic zones (Fig. 4C). High levels of expression were
also observed in the articular chondrocytes (data not shown)
and within the chondrocytes of the developing secondary
ossification center (Fig. 4D) of the 10-day-old tibias. All
control sections incubated with normal rabbit serum were nega-
tive (Fig. 4E). The immunolocalization results clearly show that
lipocalin 2 is expressed by murine growth plate chondrocytes and
this confirms our qRT-PCR data from primary murine chondro-
cytes (Fig. 2C). In the epiphyses of older mice, lipocalin 2 appears
to be present in all growth plate maturational zones. However, in
the growth plates of younger mice, it is more restricted to the
maturing hypertrophic cells.
Mechanism of Dex-induced lipocalin 2 expression in chon-
drocytes. Incubating ATDC5 cells together with Dex and CHX
caused a further increase in lipocalin 2 expression, suggesting
that CHX was blocking the synthesis of a protein involved in
lipocalin 2 repression (Fig. 5A). The competitive glucocorti-
coid receptor (GR) antagonist RU-486 caused lipocalin 2
expression to return to basal levels in the presence of Dex (Fig.
5B) (13-fold change in the presence of RU-486 and Dex vs.
39-fold change with Dex alone, P  0.01). As with most
steroidal competitive antagonists, RU-486 exhibits partial ag-
onist properties under certain conditions (74), and this could
explain the increase in lipocalin 2 expression with RU-486
alone (Fig. 5B).
Functional effects of lipocalin 2 on chondrocyte prolifera-
tion and differentiation. To identify the possible physiological
effect of Dex-induced lipocalin 2 expression on chondrocyte
dynamics we determined, in initial studies, the effects of both
lipocalin 2 overexpression (Fig. 6A) and recombinant lipocalin
2 on ATDC5 proliferation. Proliferation was significantly re-
duced (P  0.001) in overexpressing cells (Fig. 6B) and those
treated with recombinant lipocalin 2 (Fig. 6C). The reduction
in proliferation by recombinant lipocalin 2 was modest (23.1%
Fig. 3. Lipocalin 2 expression with antiproliferative agents. A: proliferation in
chondrogenic ATDC5 cells cultured in serum-free medium (SFM), or in the
presence of TNF (10 ng/ml) or ceramide (Cer.; 40 M) for 48 h. Proliferation
was measured by [3H]thymidine incorporation as previously described (n 
 6;
***P  0.001 vs. control, **P  0.01 vs. control). B: lipocalin 2 and -actin
protein expression in ATDC5 cells as measured by Western blotting after
exposure to SFM, TNF (10 ng/ml) or ceramide (40 M) for 48 h.
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at 10 g/ml), whereas a more dramatic effect (49.1%) was
noted in the overexpressing cells. This difference is likely to be
due to the unstable nature of synthetic recombinant proteins;
therefore overexpressing cells were used for further analysis.
Lipocalin-2 overexpression caused an increase in collagen type
X expression (4-fold, P  0.001; Fig. 7A). The effects of
lipocalin-2 overexpression on chondrocyte proliferation (64%
reduction vs. control cells, P  0.001) and collagen type X
expression (8-fold increase vs. control, P  0.001) were
further amplified by the addition of 106 M Dex (Figs. 6B and
7A). This apparent synergistic effect of Dex and lipocalin 2 on
proliferation and collagen type X expression may be in re-
sponse to the further increase in lipocalin 2 expression (140-
fold, P  0.001) noted in the Dex-treated overexpressing cells
(Fig. 7B).
DISCUSSION
GCs are the most effective anti-inflammatory agents known.
However, in children their long-term use leads to growth
retardation through a combination of systemic effects through
the GH-IGF axis and direct effects on the growth plate (3, 49).
The exact mechanisms by which GCs exert their effects at the
growth plate are still unclear but may be related to a reduction
in chondrocyte proliferation combined with an increase in
apoptosis, in addition to alterations in IGF-I signaling mecha-
nisms (50). Murine in vivo studies carried out by us (unpub-
lished observations), and others (60), have demonstrated that,
after 1 wk of Dex treatment, the total width of the growth plate
in 3-wk-old mice is significantly decreased due to a decrease in
the width of the proliferative zone. In addition, we (10, 52)
have previously used the murine chondrogenic ATDC5 cell
line to show that, in vitro, Dex causes a significant reduction
chondrocyte proliferation and an increase in alkaline phospha-
tase (ALP) activity, a known marker of terminally differenti-
ating chondrocytes. In this study, we identified a number of
chondrocyte genes up- or downregulated by Dex. Some of
these, such as lipocalin 2, IGF-I, DMP1, and CTGF, have
previously been shown to play an important role in the growth
plate and were therefore selected for further analysis (29, 30,
63, 72).
We confirmed that CTGF, integrin 10, DMP1, SGCK, and
lipocalin 2 were upregulated by Dex in ATDC5 cells. The Wnt
antagonist SFRP-2, the proteoglycan Lumican, and IGF-I were
all downregulated by Dex in the microarray, although only
Fig. 4. Lipocalin 2 localization in murine proximal tibia and metatarsal. A: in metatarsals from 17-day-old fetal mice, lipocalin 2 is poorly expressed in
the proliferating chondrocytes (P) and in the mineralizing zone (M); however, strong positive staining is present in prehypertrophic and hypertrophic
chondrocytes (arrows) (H) (scale bar, 400 m). B: in 10-day-old growth plate, lipocalin 2 expression is localized to proliferating (P) and prehypertrophic
chondrocytes (PH). C: a similar localization was observed in 5-wk-old growth plate (scale bar, 200 m), where intense lipocalin 2 staining is present in
the proliferating (P), hypertrophic (H), and reserve zones (R) (arrows). D: lipocalin 2 is also present in hypertrophying chondrocytes of the developing
secondary ossification center (arrows) of 10-day-old growth plate (scale bar, 200 m). E: all control sections incubated with normal rabbit serum were
negative.
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IGF-I was confirmed as being downregulated after qPCR
analysis. Variations in results between microarray and qPCR
analysis have been widely reported and is caused by a number
of factors, including the microarray normalization technique
used, measurement of spot intensity in the microarray, and
tissue preparation between experiments (47). CTGF, a down-
stream mediator of transforming growth factor-, is a critical
growth factor for chondrocyte proliferation and differentiation,
which has previously been shown to be upregulated by Dex in
the chondrocytic HCS-2.8 cell line (38). DMP1-null mice
display irregular and highly expanded growth plates, due to
both a widening of the proliferation and hypertrophic zones,
leading to a phenotype resembling dwarfism and chondrodys-
plasia (20). Interestingly, a recent study describing Affymetrix
microarray on Dex-treated primary chondrocytes also found
that DMP1 expression was significantly changed (31). The
finding that Dex induces integrin 10 expression has not been
previously reported. However, interestingly, it has recently
been shown that integrin 10-null mice display growth retar-
dation due to increased apoptosis of growth plate chondro-
cytes (4). SGCK is a serine kinase that has a catalytic
domain homologous to that of Akt and can be activated by
PI 3-kinase, making it an important signaling molecule in
growth factor and insulin-dependent signaling pathways.
SGCK has previously been shown to be upregulated in
osteoblasts in response to Dex (40).
Lipocalin 2, also known as neutrophil-associated gelatinase
lipocalin (NGAL), was originally identified as a 25-kDa pro-
tein that binds to small lipophilic substances such as bacteria-
derived lipopolysaccharide (LPS). Since then, the known ac-
tions of lipocalin 2 have grown, and lipocalin 2 has now been
Fig. 6. Effect of increased lipocalin 2 expression on chondrocyte proliferation.
A: lipocalin 2 overexpression in ATDC5 cells was confirmed by PCR of
lipocalin 2, puromycin resistance gene, and GAPDH (I); and Western blotting
for lipocalin 2 and -actin loading control (II). OE, lipocalin overexpressing;
C, control cells containing empty vector only. B: proliferation of lipocalin
2-overexpressing cells as measured by [3H]thymidine incorporation. Trans-
fected chondrogenic ATDC5 cells (day 8 of maturation) were incubated with
or without 106 M Dex for 48 h. C: ATDC5 proliferation as measured by
[3H]thymidine incorporation following 48-h incubation with recombinant
lipocalin 2 protein (5–20 g/ml, day 8 of ATDC5 maturation; n 
 6). ***P 
0.001 vs. control.
Fig. 5. Involvement of the glucocorticoid (GC) receptor (GR) in GC-
induced lipocalin 2 expression in ATDC5 cells. A: lipocalin 2 expression
with dexamethasone (Dex) plus the protein synthesis blocker cyclohexi-
mide (CHX). Chondrogenic ATDC5 cells (day 8) were preincubated for 30
min with CHX (8 g/ml) before addition of 106 M Dex for 48 h.
B: lipocalin 2 expression with Dex plus the GR antagonist RU-486.
Chondrogenic ATDC5 cells (day 8) were incubated with 106 M Dex 
RU-486 (105 M) for 48 h. Data are expressed as means 	 SE; n 
 3.
***P  0.001 vs. control; P  0.05 vs. Dex.
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linked with a wide range of different functions, including
partuition, inflammation, differentiation, apoptosis, and acute-
phase immunity. Lipocalin 2-null mice have compromised
immunity against bacterial infection (6) but have no obvious
skeletal phenotype (22). Originally termed SIP24 (superinduc-
ible protein-24), lipocalin 2 is known to be induced by a number
of factors and conditions, such as LPS, CHX, serum, FGF2,
prostaglandin F2, oxidative stress, partuition, and Dex (43).
In this study, we have shown that lipocalin 2 expression is
significantly increased with Dex treatment in murine chondro-
genic ATDC5 cells. This increased expression was Dex con-
centration dependent and reached a plateau after 48-h Dex.
Other antiproliferative treatments such as SFM and ceramide
(46) did not cause an increase in lipocalin 2 expression,
suggesting that the increase in lipocalin 2 expression by Dex
observed in this study is not directly due to a reduction in
proliferation. Previous studies have shown that lipocalin 2
expression is increased in the presence of proinflammatory
mediators and inflammatory cytokines such as LPS (62, 73),
TNF, and IL-17 (58), which is in agreement with the small
increase in lipocalin 2 expression observed with TNF in this
present study.
In primary murine costochondral chondrocytes isolated from
the rib cages of 1-day-old mice, an increase in lipocalin 2
expression was also observed, and, although significant, this
increase was smaller than that seen in ATDC5 cells. ATDC5
cells were originally isolated from a differentiating culture of
AT805 teratocarcinoma cells, which display a fibroblast-like
phenotype until the addition of insulin, which promotes their
differentiation into chondrocytes (1). These cells are a useful
model for studying chondrogenesis due to the fact that their
temporal sequence of maturation directly mirrors the matura-
tional phases within the growth plate. In addition, the cell
population differentiates collectively, so that all the cells are at
the same stage of differentiation at the same time. However,
because of this, they cannot be compared directly to primary
costochondral chondrocytes, which are isolated as a population
of chondrocytes at all stages of differentiation. The fact that
ATDC5 cells and primary costochondral chondrocytes com-
prise two different phenotypes could explain the differences in
the magnitude of lipocalin 2 expression observed in this study.
In addition, it has previously been shown that lipocalin 2
protein expression is increased during the neoplastic transfor-
mation of chondrogenic lineage cells (73), which may also
contribute to the large increase in lipocalin 2 expression ob-
served in ATDC5 cells.
The expression of lipocalin 2 in primary chondrocytes was
supported by the finding that lipocalin 2 was expressed in the
metatarsals of embryonic mice. Lipocalin 2 has previously
shown to be expressed in the liver, spleen, lung, muscle, heart,
and tibia of embryonic mice (25, 63), and within the tibia of
embryonic rats, the rat homologue of lipocalin 2 neu-related
lipocalin (NRL) is localized to the prehypertophic chondro-
cytes (73), supporting the findings of this study. It has previ-
ously been found that ALP has a similar pattern of localization
within the growth plate (50), suggesting that, like ALP, lipoca-
lin 2 may be a marker for chondrocyte differentiation. Inter-
estingly, we have shown that, in 10-day-old and 5-wk-old
mice, lipocalin 2 is more prominent in the proliferative chon-
drocytes, suggesting that the localization of lipocalin 2 expres-
sion within the growth plate is age dependent. Differences in
lipocalin 2 expression between adult and fetal tissue have
previously been described, with a general decline in expression
in conjunction with aging (25). This, together with similarities
in expression to ALP, and previous studies showing the pro-
differentiating effects of lipocalin 2 in epithelial cells (71),
further supports the hypothesis that lipocalin 2 may have a role
in the regulation of chondrocyte differentiation.
In an attempt to identify some of the mechanisms involved
in Dex-induced lipocalin 2 expression, the GR antagonist
RU-486 was incubated alone or with Dex in ATDC5 cells.
Results showed that, in the presence of RU-486 alone, lipocalin
2 expression was increased to some extent. RU-486 is a
competitive antagonist for the GR, and, by nature, such antag-
onists often display some agonist activity at the receptor they
competitively bind to, accounting for the increases in lipocalin
2 expression observed here. When RU-486 and Dex were
incubated together, lipocalin 2 expression could no longer be
induced with Dex. Analysis of the lipocalin 2 sequence with
MatInspector (www.genomatix.de) confirmed previous reports
of two GC response elements (GRE) in the 5-regulatory
region of the lipocalin 2 promoter (8, 25). The presence of
GRE in the promoter region of lipocalin 2 suggested that this
gene could be a direct target of the GR complex. This was
supported by the fact that the Dex-induced increase in lipocalin
2 mRNA levels was not inhibited by CHX, a protein synthesis
inhibitor. Interestingly, CHX in fact caused a further increase
in lipocalin 2 expression. This finding has been previously
Fig. 7. Combined effect of lipocalin 2 and Dex on ATDC5 cell differentiation.
A: type X collagen expression in lipocalin 2-overexpressing chondrogenic
ATDC5 cells incubated with or without 106 M Dex for 48 h. B: effect of Dex
on lipocalin 2 expression in chondrogenic ATDC5 cells overexpressing lipoca-
lin 2. Cells were incubated with 106 M Dex for 48 h, and lipocalin 2
expression was measured by qPCR Data are expressed as means 	 SE; n 

3–6. ***P  0.001 vs. control; P  0.05 vs. Dex Empty; P  0.05 vs.
lipocalin Control.
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reported (13) and could be due to CHX blocking the synthesis
of a lipocalin 2 or Dex repressor.
The importance of lipocalin 2 in GC-induced growth retar-
dation was further supported with the finding that its overex-
pression caused a reduction in ATDC5 proliferation and an
increase in differentiation, an effect that is similar to that seen
with GC-treated ATDC5 cells (49, 52). The effects on prolif-
eration were reproduced with the addition of lipocalin 2 re-
combinant protein, again supporting the hypothesis that lipoca-
lin 2 is influencing chondrocyte dynamics in a similar way to
GCs. Interestingly, the effects of lipocalin 2 overexpression on
proliferation and differentiation were exacerbated with Dex,
and lipocalin 2 expression in transfected cells was increased
more than would be expected from the additive effects of Dex
and lipocalin 2 expression alone. The synergistic effect of Dex
and LPS on lipocalin 2 expression has previously been de-
scribed (65); however, these findings suggest that lipocalin 2
itself may play a role in mediating the effects of Dex. It is
therefore possible that lipocalin 2 could be exacerbating Dex-
induced growth retardation by interacting directly with Dex to
inhibit chondrocyte proliferation and increase differentiation.
Lipocalin 2 has previously been shown to be regulated by
Dex in dendritic cells (65) and fibroblast-derived murine L-
cells (25); however, its stimulation in chondrocytes has not
previously been reported. This study has shown that the acute-
phase binding protein lipocalin 2 is markedly increased in
chondrocytes in response to Dex and may play a role in
mediating GC effects at the growth plate. It is widely acknowl-
edged that GCs are likely to affect a wide range of complex
regulatory mechanisms, including Akt and MAPK signaling
(10), cell cycle signaling (9), and the NF-B pathway (2).
Although this paper has suggested that lipocalin 2 may be one
mechanism involved in GC-induced growth retardation, it is
likely that a number of other regulatory mechanisms are also
involved. However, in this study we have identified that li-
pocalin 2 expression is altered in Dex-treated chondrocytes and
that overexpression of lipocalin 2 results in a similar phenotype
as that seen in Dex-treated cells. This suggests that the in-
creased expression of lipocalin 2 by Dex has the potential to
modify chondrocyte activities.
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